Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: A report from the Japanese Childhood Cancer and Leukemia Study Group

Pediatric Blood and Cancer

Volumn 55, Issue 7, 2010, Pages 1287-1295

  Yamaji, Kazutaka ^a   Okamoto, Tomomi ^a   Yokota, Shohei ^a   Watanabe, Arata ^a   Horikoshi, Yasuo ^a   Asami, Keiko ^a   Kikuta, Atsushi ^a   Hyakuna, Nobuyuki ^a   Saikawa, Yutaka ^a   Ueyama, Junichi ^a   Watanabe, Tsutomu ^a   Okada, Masahiko ^a   Taga, Takashi ^a   Kanegane, Hirokazu ^a   Kogawa, Kazuhiro ^a   Chin, Motoaki ^a   Iwai, Asayuki ^a   Matsushita, Takeshi ^a   Shimomura, Yasuto ^a   Hori, Toshinori ^a   Tsurusawa, Masahito ^a   more..

^a AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Augmented therapy; Childhood ALL; Minimal residual disease; MRD stratification

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; HYDROCORTISONE; IMMUNOGLOBULIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PIRARUBICIN; PREDNISOLONE; T LYMPHOCYTE RECEPTOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RISK; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE REARRANGEMENT; HUMAN; IMMUNOPHENOTYPING; INFANT; INFECTION; JAPANESE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PANCREATITIS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; MALE; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 78049300632     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22620     Document Type: Article

References (29)

1. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 4-6.
2. Steinherz PG, Gaynon PS, Breneman JC, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia-The importance of early marrow response: Report from the Children's Cancer Group. J Clin Oncol 1996; 14: 389-398.
3. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia 2000; 14: 2205-2222.
4. van Dongen JJM, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-1738.
5. Campana D, Coustan-Smith E. Minimal residual disease studies by flow cytometry in acute leukemia. Acta Haematol 2004; 112: 8-15.
6. Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591-598.
7. Nyvold C, Madsen HO, Ryder LP, et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002; 99: 1253-1258.
8. Dworzak MN, Fröschl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99: 1952-1958.
9. Willemse MJ, Seriu T, Hettinger K, et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 2002; 99: 4386-4393.
10. Zhou J, Goldwasser MA, Li A, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL consortium protocol 95-01. Blood 2007; 110: 1607-1611.
11. Van der Velden VH, Corral L, Valsecchi MG, et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009; 23: 1073-1079.
12. Okamoto T, Yokota S, Katano N, et al. Minimal residual disease in early phase of chemotherapy reflects poor outcome in children with acute lymphoblastic leukemia-A retrospective study by the children's cancer and leukemia study group in Japan. Leuk Lymphoma 2002; 43: 1001-1006.
13. Schultz KR, Pullen DJ, Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007; 109: 926-935.
14. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study. Blood 2008; 111: 5477-5485.
15. Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunogloblin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771-782.
16. Cutting RJ, Richards S, Hancock J, et al. Post-remission MRD kinetics in children with acute lymphoblastic leukaemia receiving augmented BFM consolidation compared with other regimens: results of the medical research council trial UKALL 2003. Blood 2008; 112: 539 (abstr 1516).
17. Hori T, Yamaji K, Yokota S, et al. Augmented therapy for MRD-positive patients with acute lymphoblastic leukemia can reduce the MRD levels and the risk of relapse: A report from the Japanese childhood cancer and leukemia study group ALL2000 MRD pilot study. Blood 2008; 112: 117 (abstr 301).
18. Tsurusawa M, Katano N, Yamamoto Y, et al. Improvement in CNS protective treatment in non-high-risk childhood acute lymphoblastic leukemia: Report from the Japanese Children's Cancer and Leukemia Study Group. Med Pediatr Oncol 1999; 32: 259-266.
19. Watanabe A, Katano N, Kikuta A, et al. Strategy of cumulative dose reduction of drugs with late effects: Children's Cancer and Leukemia Study Group of Japan (CCLSG), CCLSG ALL941 protocol study. Blood 2003; 102: 223a (abstr 783).
20. Dantchev D, Paintrand M, Hayat M, et al. Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THPADM) as observed by electron and light microscopy. J Antibiot (Tokyo) 1979; 32: 1085-1086.
21. Chauvergne J, Fumoleau P, Cappelaere P, et al. Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: Study of the clinical screening group of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 1993; 29A: 350-354.
22. Szczepaski T, Willemse MJ, van Wering ER, et al. Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia 2001; 15: 1415-1423.
23. Margolin JF, Steuber CP, Poplack DG. Principles and practice of pediatric oncology, 5th edition. Philadelphia, PA, Lippincot Williams & Wilkins; 2006. pp. 568-570.
24. Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BF M95. Blood 2008; 111: 4477-4489.
25. Millot F, Suciu S, Philippe N, et al. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic Leukemia and lymphoblastic lymphoma: Results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Clin Oncol 2001; 19: 1935-1942.
26. Harris MB, Shuster JJ, Pullen J, et al. Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: A Pediatric Oncology Group Study. Leukemia 2000; 14: 1570-1576.
27. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. Blood 2000; 95: 3310-3322.
28. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 2008; 111: 2548-2555.
29. van der Velden VH, Panzer-Grümayer ER, Cazzaniga G, et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 2007; 21: 706-713.